{
    "organizations": [],
    "uuid": "47f1684e6754e9f9a5a5a10decbf7ddbc2248aa7",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/21/globe-newswire-fibrogen-to-report-fourth-quarter-and-full-year-2017-financial-results-on-tuesday-february-27-2018.html",
    "ord_in_thread": 0,
    "title": "FibroGen to Report Fourth Quarter and Full Year 2017 Financial Results on Tuesday, February 27, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "SAN FRANCISCO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that it will report fourth quarter and full year 2017 financial results on Tuesday, February 27, 2018 after market close, and will host a conference call to discuss financial results and provide a business update at 5:00 p.m. ET (2:00 p.m. PT).\nConference Call and Audio Webcast\nInterested parties may access a live audio webcast of the conference call via the investor section of the FibroGen website, www.fibrogen.com . It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software. A replay of the webcast will be available shortly after the call for a period of two weeks. To access the replay, please dial (888) 843-7419 (domestic) or (630) 652-3042 (international), and use passcode 46307822#.\nDial-In Information\nLive (U.S./Canada): (888) 771-4371\nLive (International): (847) 585-4405\nConfirmation number: 46307822\nAbout FibroGen\nFibroGen, Inc., headquartered in San Francisco, CA with subsidiary offices in Beijing and Shanghai, PRC, is a leading science-based biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology and clinical development to advance innovative medicines for the treatment of anemia, and fibrotic disease and cancer. Roxadustat, the companyâ€™s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD) with the exception of China, where a new drug application is currently under review by the CFDA for regulatory approval. Roxadustat is also entering Phase 3 development for anemia in myelodysplastic syndromes (MDS). Pamrevlumab, a fully-human monoclonal anti-CTGF antibody, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit www.fibrogen.com .\nContact\nKaren L. Bergman\nVice President, Investor Relations and\nCorporate Communications\nFibroGen, Inc.\nkbergman@fibrogen.com\n(415) 978-1433\nSource:FibroGen, Inc",
    "published": "2018-02-21T15:00:00.000+02:00",
    "crawled": "2018-02-21T15:47:38.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "san",
        "francisco",
        "globe",
        "newswire",
        "fibrogen",
        "nasdaq",
        "fgen",
        "biopharmaceutical",
        "company",
        "today",
        "announced",
        "report",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "tuesday",
        "february",
        "market",
        "close",
        "host",
        "conference",
        "call",
        "discus",
        "financial",
        "result",
        "provide",
        "business",
        "update",
        "et",
        "pt",
        "conference",
        "call",
        "audio",
        "webcast",
        "interested",
        "party",
        "may",
        "access",
        "live",
        "audio",
        "webcast",
        "conference",
        "call",
        "via",
        "investor",
        "section",
        "fibrogen",
        "website",
        "recommended",
        "listener",
        "access",
        "website",
        "minute",
        "prior",
        "start",
        "call",
        "download",
        "install",
        "necessary",
        "audio",
        "software",
        "replay",
        "webcast",
        "available",
        "shortly",
        "call",
        "period",
        "two",
        "week",
        "access",
        "replay",
        "please",
        "dial",
        "domestic",
        "international",
        "use",
        "passcode",
        "information",
        "live",
        "live",
        "international",
        "confirmation",
        "number",
        "fibrogen",
        "fibrogen",
        "headquartered",
        "san",
        "francisco",
        "ca",
        "subsidiary",
        "office",
        "beijing",
        "shanghai",
        "prc",
        "leading",
        "biopharmaceutical",
        "company",
        "discovering",
        "developing",
        "pipeline",
        "therapeutic",
        "company",
        "applies",
        "pioneering",
        "expertise",
        "factor",
        "hif",
        "connective",
        "tissue",
        "growth",
        "factor",
        "ctgf",
        "biology",
        "clinical",
        "development",
        "advance",
        "innovative",
        "medicine",
        "treatment",
        "anemia",
        "fibrotic",
        "disease",
        "cancer",
        "roxadustat",
        "company",
        "advanced",
        "product",
        "candidate",
        "oral",
        "small",
        "molecule",
        "inhibitor",
        "hif",
        "prolyl",
        "hydroxylase",
        "activity",
        "worldwide",
        "phase",
        "clinical",
        "development",
        "treatment",
        "anemia",
        "chronic",
        "kidney",
        "disease",
        "ckd",
        "exception",
        "china",
        "new",
        "drug",
        "application",
        "currently",
        "review",
        "cfda",
        "regulatory",
        "approval",
        "roxadustat",
        "also",
        "entering",
        "phase",
        "development",
        "anemia",
        "myelodysplastic",
        "syndrome",
        "md",
        "pamrevlumab",
        "monoclonal",
        "antibody",
        "phase",
        "clinical",
        "development",
        "treatment",
        "idiopathic",
        "pulmonary",
        "fibrosis",
        "ipf",
        "pancreatic",
        "cancer",
        "duchenne",
        "muscular",
        "dystrophy",
        "dmd",
        "fibrogen",
        "also",
        "developing",
        "biosynthetic",
        "cornea",
        "china",
        "information",
        "please",
        "visit",
        "contact",
        "karen",
        "bergman",
        "vice",
        "president",
        "investor",
        "relation",
        "corporate",
        "communication",
        "fibrogen",
        "kbergman",
        "source",
        "fibrogen",
        "inc"
    ]
}